Jul 7, 2026 · 6 min
Rivian’s Funding Plan Shakes Markets as Fiserv and Crinetics Rally
Rivian Falls, Fiserv Rises, Crinetics Pharmaceuticals Gains on Vertex Deal
The episode shows how financing needs, potential payments-industry consolidation, and a major pharmaceutical acquisition can quickly reshape individual stocks.
- 1Rivian shares plunged after announcing a $1.5 billion sale to fund equity contributions for a Department of Energy loan.
- 2Fiserv gained as major Wall Street banks reportedly discussed acquiring its debit network.
- 3Crinetics Pharmaceuticals rose after Vertex agreed to a $10 billion acquisition, while Western Digital fell in a chipmaker sell-off.
Don't miss
Rivian’s stock plunge after the company announced a $1.5 billion share sale to support equity contributions for a Department of Energy loan.
The brief
Host Paul Sweeney and Bloomberg’s Juni Legru frame a market-movers report around corporate actions that sent several stocks sharply in opposite directions.
Rivian plunged after announcing a $1.5 billion share sale to fund equity contributions for a Department of Energy loan, putting financing pressure at the center of the move.
Fiserv moved higher amid reports that major Wall Street banks were discussing an acquisition of its debit network, turning possible industry consolidation into a stock catalyst.
Crinetics Pharmaceuticals gained after Vertex agreed to a $10 billion acquisition, while Western Digital declined as chipmakers faced a broader sector sell-off.
The episode’s central contrast is clear: funding demands weighed on Rivian, while takeover possibilities and strategic deals lifted other companies.
Featuring
Bloomberg L.P.Books & mentions
Listen to the full episode and explore every guest, topic, and moment on PodLume.